ATE189771T1 - Zubereitung mit kontrollierter freisetzung, die ein morphinsalz enthält - Google Patents

Zubereitung mit kontrollierter freisetzung, die ein morphinsalz enthält

Info

Publication number
ATE189771T1
ATE189771T1 AT94912116T AT94912116T ATE189771T1 AT E189771 T1 ATE189771 T1 AT E189771T1 AT 94912116 T AT94912116 T AT 94912116T AT 94912116 T AT94912116 T AT 94912116T AT E189771 T1 ATE189771 T1 AT E189771T1
Authority
AT
Austria
Prior art keywords
morphine
controlled release
preparations
manufacture
preparation containing
Prior art date
Application number
AT94912116T
Other languages
English (en)
Inventor
Birgitta Olsson
Maritta Anneli Chefrad
Gert Ragnarsson
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20389415&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE189771(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Application granted granted Critical
Publication of ATE189771T1 publication Critical patent/ATE189771T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT94912116T 1993-03-30 1994-03-24 Zubereitung mit kontrollierter freisetzung, die ein morphinsalz enthält ATE189771T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9301057A SE9301057L (sv) 1993-03-30 1993-03-30 Beredning med kontrollerad frisättning
PCT/SE1994/000264 WO1994022431A1 (en) 1993-03-30 1994-03-24 Controlled release preparation containing a salt of morphine

Publications (1)

Publication Number Publication Date
ATE189771T1 true ATE189771T1 (de) 2000-03-15

Family

ID=20389415

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94912116T ATE189771T1 (de) 1993-03-30 1994-03-24 Zubereitung mit kontrollierter freisetzung, die ein morphinsalz enthält

Country Status (25)

Country Link
US (1) US5614218A (de)
EP (1) EP0642335B2 (de)
JP (1) JP4107678B2 (de)
KR (1) KR100316206B1 (de)
CN (1) CN1104891C (de)
AT (1) ATE189771T1 (de)
AU (1) AU680891C (de)
CA (1) CA2135639C (de)
CZ (1) CZ284924B6 (de)
DE (1) DE69423028T3 (de)
DK (1) DK0642335T4 (de)
EE (1) EE03147B1 (de)
ES (1) ES2144516T5 (de)
FI (1) FI113743B (de)
GR (1) GR3033325T3 (de)
HU (1) HU227344B1 (de)
LV (1) LV10684B (de)
NO (1) NO310015B1 (de)
NZ (1) NZ263632A (de)
PL (1) PL175326B1 (de)
PT (1) PT642335E (de)
RU (1) RU2136283C1 (de)
SE (1) SE9301057L (de)
SK (1) SK280362B6 (de)
WO (1) WO1994022431A1 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
AU735113C (en) * 1991-12-24 2007-06-14 Mundipharma Medical Gmbh Opioid formulations for treating pain
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
NZ260408A (en) 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
IL109944A (en) † 1993-07-01 1998-12-06 Euro Celtique Sa Sustained release dosage unit forms containing morphine and a method of preparing these sustained release dosage unit forms
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US20020006438A1 (en) * 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
DE19607395C2 (de) * 1996-02-28 2002-11-21 Lohmann Therapie Syst Lts Salze aus einem kationischen narkotischen Analgetikum mit einem anionischen nichtnarkotischen Analgetikum, Verfahren zu deren Herstellung und die diese Salze enthaltenden pharmazeutischen Präparate
US6245351B1 (en) 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6066339A (en) * 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
DE19901683B4 (de) * 1999-01-18 2005-07-21 Grünenthal GmbH Analgetikum mit kontrollierter Wirkstofffreisetzung
FR2794646B1 (fr) 1999-06-09 2001-09-21 Ethypharm Lab Prod Ethiques Microgranules de sulfate de morphine, procede de preparation et composition les contenant
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
KR100889069B1 (ko) 1999-10-29 2009-03-17 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
BR0115382A (pt) 2000-10-30 2003-09-16 Euro Celtique Sa Formulações para liberação controlada de hidrocodona, método de produzir analgesia efetiva, processo de preparação de uma forma farmacêutica de um sólido oral de liberação controlada, liberação controlada da forma farmacêutica oral e uso da forma farmacêutica
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
AU4061702A (en) * 2001-05-15 2003-04-03 Mcneil-Ppc, Inc. Dip coating compositions containing starch or dextrin
US20030070584A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
US20030072731A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing starch or dextrin
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
EP2957281A1 (de) 2001-09-21 2015-12-23 Egalet Ltd. Polymer-freigabe-system
US8309118B2 (en) * 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
AU2003225837B2 (en) * 2002-03-15 2008-11-06 Forest Laboratories Holdings Limited NE and 5-HT reuptake inhibitors for treating visceral pain syndromes
US7429619B2 (en) * 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
PT1551372T (pt) * 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc Subunidade de sequestração e composições e métodos relacionados
AU2003272601B2 (en) * 2002-09-20 2009-05-07 Alpharma Pharmaceuticals, Llc Sustained-release opioid formulations and methods of use
EP1546120A4 (de) * 2002-10-04 2006-11-22 Pharmacia Corp Pharmazeutische zusammensetzung zur behandlung von parkinson-krankheit
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20060003004A1 (en) * 2002-10-25 2006-01-05 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
US20040228830A1 (en) * 2003-01-28 2004-11-18 Collegium Pharmaceutical, Inc. Multiparticulate compositions of milnacipran for oral administration
ATE495732T1 (de) 2003-03-26 2011-02-15 Egalet As Morphin-system mit kontrollierter freisetzung
MY135852A (en) * 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
SI1575565T1 (sl) * 2003-08-08 2010-04-30 Biovail Lab Int Srl Tableta bupropion hidroklorida z modificiranim sprošŽŤanjem
EP1810678A1 (de) 2006-01-19 2007-07-25 Holger Lars Hermann Verwendung einer Kombination von Morphin und Naloxon zur Drogensubstitution
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US20080075768A1 (en) * 2006-07-21 2008-03-27 Vaughn Jason M Hydrophobic opioid abuse deterrent delivery system using opioid antagonists
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
EP2155167A2 (de) 2007-06-04 2010-02-24 Egalet A/S Pharmazeutische zusammensetzungen mit gesteuerter freisetzung für verlängerte wirkung
PL2187873T3 (pl) 2007-08-13 2019-01-31 Abuse Deterrent Pharmaceutical Llc Leki odporne na nadużywanie, metoda stosowania i metoda wytwarzania
GB2460915B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
EP2393484A1 (de) 2009-02-06 2011-12-14 Egalet Ltd. Gegen missbrauch durch alkoholeinnahme widerstandsfähige zusammensetzung mit unmittelbarer freisetzung
EP2448406B1 (de) 2009-02-26 2016-04-20 Relmada Therapeutics, Inc. Oral einnehmbare pharmazeutische zusammensetzungen aus 3-hydroxy-n-methylmorphinan mit verzögerter freisetzung und verwendungsverfahren dafür
EP2445487A2 (de) 2009-06-24 2012-05-02 Egalet Ltd. Retard-formulierungen
CA2798702A1 (en) 2010-05-11 2011-11-17 Cima Labs Inc. Alcoholresistant metoprolol-containing extended-release oral dosage forms
AU2011276170B2 (en) 2010-07-06 2016-03-10 Grunenthal Gmbh Novel gastro- retentive dosage forms comprising a GABA Analog and an opioid
KR20150059167A (ko) 2012-07-06 2015-05-29 에갈렛 리미티드 제어된 방출을 위한 남용 제지 약학적 조성물
US20140275149A1 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
AU2014306759B2 (en) 2013-08-12 2018-04-26 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2016010771A1 (en) 2014-07-17 2016-01-21 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
CA2964628A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
AU2018390826B2 (en) 2017-12-20 2024-09-12 Purdue Pharma L.P. Abuse deterrent morphine sulfate dosage forms

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
CA2007181C (en) * 1989-01-06 1998-11-24 Angelo Mario Morella Sustained release pharmaceutical composition
SE8902699D0 (sv) * 1989-08-09 1989-08-09 Lejus Medical Ab Diltiazem containing pharmaceutical compositios
DE4105480A1 (de) * 1991-02-21 1992-08-27 Boehringer Mannheim Gmbh Verbesserte aktivierung von rekombinanten proteinen
US5273760A (en) † 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5478577A (en) † 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
SE9202250D0 (sv) * 1992-07-29 1992-07-29 Gacell Lab Ab Controlled release morphine preparation

Also Published As

Publication number Publication date
CN1104891C (zh) 2003-04-09
GR3033325T3 (en) 2000-09-29
ES2144516T3 (es) 2000-06-16
NO944565D0 (no) 1994-11-29
SE9301057L (sv) 1994-10-01
CZ298694A3 (en) 1995-05-17
CZ284924B6 (cs) 1999-04-14
DK0642335T4 (da) 2005-05-23
LV10684A (lv) 1995-06-20
SE9301057D0 (sv) 1993-03-30
NO310015B1 (no) 2001-05-07
CA2135639C (en) 2006-02-07
HU227344B1 (en) 2011-04-28
FI945621L (fi) 1994-11-29
RU2136283C1 (ru) 1999-09-10
NZ263632A (en) 1997-06-24
US5614218A (en) 1997-03-25
AU6439394A (en) 1994-10-24
KR100316206B1 (ko) 2002-11-09
LV10684B (en) 1996-02-20
EP0642335B1 (de) 2000-02-16
DE69423028T2 (de) 2001-01-18
HU9403437D0 (en) 1995-02-28
FI113743B (fi) 2004-06-15
DE69423028D1 (de) 2000-03-23
EE03147B1 (et) 1999-02-15
JPH08501319A (ja) 1996-02-13
AU680891C (en) 2002-01-03
CN1106608A (zh) 1995-08-09
FI945621A0 (fi) 1994-11-29
EP0642335B2 (de) 2005-01-19
DE69423028T3 (de) 2006-07-20
SK280362B6 (sk) 1999-12-10
CA2135639A1 (en) 1994-10-13
PT642335E (pt) 2000-08-31
EP0642335A1 (de) 1995-03-15
JP4107678B2 (ja) 2008-06-25
AU680891B2 (en) 1997-08-14
NO944565L (no) 1994-11-29
HUT71417A (en) 1995-11-28
SK143794A3 (en) 1995-06-07
RU94046147A (ru) 1996-11-10
PL306421A1 (en) 1995-04-03
PL175326B1 (pl) 1998-12-31
WO1994022431A1 (en) 1994-10-13
ES2144516T5 (es) 2005-07-01
DK0642335T3 (da) 2000-07-24

Similar Documents

Publication Publication Date Title
ATE189771T1 (de) Zubereitung mit kontrollierter freisetzung, die ein morphinsalz enthält
NZ508526A (en) Opioid formulations for treating pain
AU1534699A (en) Osmotic dosage form comprising first and second coats
ATE427101T1 (de) Orales system zur verabreichung von gepulsten dosen eines arzneistoffs
NZ509028A (en) Stable extended release oral dosage composition comprising a pseudoephedrine-containing core, the core being uniformly covered with a desloratadine-containing film
CA2093806A1 (en) Method of treating or preventing type 1 diabetes by oral administration of insulin
NZ229518A (en) Pharmaceutical dosage form for the medication of fish: method of administration and (prophylactic) treatment
ATE234602T1 (de) Verabreichungsform zur abgabe von steigenden wirkstoffdosen
GEP19991686B (en) Pharmaceutical Composition for Obtaining Effervescent Powder or Tablet, Pharmaceutical Preparation and Method for Preparing Same
GEP20002229B (en) Synthetic Membrane Vesicles, Method for Obtaining and Application of the Same
AU7239996A (en) Inhibition of tumor necrosis factor alpha
RU95101385A (ru) Продукты, содержащие g-csf и tnf связующие протеина
MY124465A (en) Reduction of infarct volume using citicoline
ES2026304A6 (es) Procedimiento de fabricacion de una forma de dosificacion de nicardipina.
EP0302714A3 (de) Pharmazeutische Zusammensetzung zur Behandlung von Knochenschwund-Krankheiten
GB1487334A (en) Pharmaceutical preparations comprising lisuride and/or physiologically tolerable salts thereof
GB1453034A (en) Pharmaceutical composition for treating spasticity
RU95100741A (ru) Способ лечения туберкулеза легких
ATE91890T1 (de) Herstellung eines arzneimittels gegen arthritis und rheumatismus.
GB1302266A (de)
HUP9900521A2 (hu) Eljárás nagyon kis dózisú hatóanyagok szilárd dózisformáinak előállítására
Mooser et al. Antihypertensive effect of diltiazem administered once and twice daily
RU97109989A (ru) Способ лечения вагинозов и вагинитов у беременных
UA15281A (uk) Спосіб лікуваhhя хроhічhої ішемічhої хвороби серця
TH22304A (th) สารเตรียมทางเภสัชกรรมแบบหลายหน่วยที่มีสารยัยยั้งปั๊มโปรตอน

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEFA Change of the company name
UEP Publication of translation of european patent specification

Ref document number: 0642335

Country of ref document: EP